Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06994806 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
A Phase 1 study of Solid Tumor Malignancies, sponsored by Kumquat Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
- 15
- Study locations
NCT06994806: Recruiting Phase 1 study of Solid Tumor Malignancies, sponsored by Kumquat Biosciences.
NCT06994806 is a Phase 1 study of Solid Tumor Malignancies that is actively recruiting participants, run by Kumquat Biosciences. The registered enrollment target is 84 participants, below the 188-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (55% lower). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06994806, a Phase 1 study of Solid Tumor Malignancies, is actively recruiting participants, sponsored by Kumquat Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
- 15
- Study locations
Study Summary
The goal of this clinical trial is to learn if KQB168 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB168. The main questions it aims to answer are: * What is the safe dose of KQB168 by itself or in combination with pembrolizumab? * Does KQB168 alone or in combination with pembrolizumab decrease the size of the tumor? * What happens to KQB168 in the body? Participants will: * Take KQB168 daily, alone or in combination with pembrolizumab * Visit the clinic about 8 times in the first 8 weeks, and then once every 3 weeks after that
Primary Outcome
Safety characterized by type, incidence, severity, timing, seriousness and relationship to study treatment of AEs, SAEs, and DLTs, from first dose of study treatment to 30 days after last dose of study treatment.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG KQB168
Study Locations (15)
Texas
- NEXT Austin - Austin
- Mary Crowley Cancer Research Centers - Dallas
- UT MD Anderson Cancer Center - Houston - Houston
- NEXT Huston - Houston
- NEXT Oncology - San Antonio
Florida
- Mayo Clinic - Jacksonville - Jacksonville
- Florida Cancer Specialists - Sarasota - Sarasota
Arizona
- Mayo Clinic - Phoenix - Phoenix
California
- USC Norris Comprehensive Cancer Center - Los Angeles
Colorado
- Sarah Cannon Cancer Institute at HealthONE - Denver
Connecticut
- Yale Cancer Center- New Haven - New Haven
Iowa
- University of Iowa - Iowa City
Minnesota
- Mayo Clinic - Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2025-06-24 |
| Est. Completion | 2028-05-31 |
| Phase | Phase 1 |
What NCT06994806 shows while recruiting
NCT06994806 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 188-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Solid Tumor Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT06994806 lists 15 locations in 10 states (Texas, Florida, Arizona).
Frequently Asked Questions
What is clinical trial NCT06994806 about?
NCT06994806 is a clinical study titled "A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies". The goal of this clinical trial is to learn if KQB168 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB168. The main questions it aims to answer are: * What is the safe dose of KQB168 by itself or in combination with pembrolizumab? * Does KQB168 alone ...
What is the current status of trial NCT06994806?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2025-06-24. Estimated completion is 2028-05-31.
What conditions does trial NCT06994806 study?
This clinical trial studies the following conditions: Solid Tumor Malignancies.
What interventions are being tested in trial NCT06994806?
The interventions under investigation include: Pembrolizumab (DRUG), KQB168 (DRUG).
Who is sponsoring clinical trial NCT06994806?
This trial is sponsored by Kumquat Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06994806 being conducted?
This trial has 15 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06994806's enrollment target sits among peer trials
84 9th of 11 higher than 3 of 11 other Solid Tumor Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
RECRUITING · Phase 1
-
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI